Hims & Hers says its offering responsible, individualized care for preventative metabolic health. More than 15,000 people have already joined Nooms program
Despite producing more weight loss, tirzepatide had lower rates of treatment discontinuation due to gastrointestinal adverse events (2.7% vs 5.6% for semaglutide)
[3] As of mid-2025, retatrutide has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the UK or Europe
Understanding when and how to adjust frequency helps you get the most from long-term treatment
Crosstalk between adipose remodeling and systemic metabolism The metabolic benefits observed at the whole-body levelincluding improved glucose tolerance, decreased hepatic enzyme levels, and normalization of circulating lipidsare likely secondary to the restoration of adipose tissue function
It accesses doses lower than the usual starter doses on our other GLP-1 programs, as well as additional doses up to 25% of the standard maintenance dose